Skip to main content
SpringerLink
Log in

Drug-Induced Nail Disorders

Incidence, Management and Prognosis

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

A large number of drugs of different classes, ranging from antibacterials to chemotherapeutic agents to psoralens, can be responsible for the development of nail changes. Drug-induced nail changes usually involve several or all 20 nails and appear in temporal correlation with drug intake. Some nail changes are asymptomatic and only cause cosmetic problems, while others cause pain and discomfort and impair manual activities or deambulation. Drug-induced nail abnormalities are usually transitory and disappear with drug withdrawal, but sometimes persist in time.

The pathogenesis of the nail changes is usually a toxic effect of the drug on the different nail constituents, but other mechanisms can be involved.

Drugs that are well known to produce nail abnormalities include cancer chemotherapeutic agents, psoralens, retinoids, tetracyclines, antimalarials and zidovudine. Arsenic poisoning is also always associated with nail changes that have medico-legal importance.

Some drugs taken during pregnancy may impair nail development of the fetus, and nail hypoplasia or other nail dystrophies will be evident in the newborn.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zaias N. The nail in health and disease. 2nd rev. ed. Norwalk: Appleton & Lange, 1990

    Google Scholar 

  2. Tosti A, Baran R, Dawber RPR. The nail in systemic diseases and drug-induced changes. In: Baran R, Dawber RPR, editors. Diseases of the nails and their management. 2nd ed. Oxford: Blackwell Scientific Publications, 1994: 175–261

    Google Scholar 

  3. Daniel III CR, Scher RK. Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol 1984; 10: 250–8

    Article  PubMed  Google Scholar 

  4. Baran R, Dawber R, Haneke E, et al. A text atlas of nail disorders. London: Martin Dunitz, 1996

    Google Scholar 

  5. Singh M, Kaur S. Chemotherapy-induced multiple Beau’s lines. Int J Dermatol 1986; 25: 590–1

    Article  PubMed  CAS  Google Scholar 

  6. Baran R. Retinoids and the nails. J Dermatol Treat 1990; 1: 151–4

    Article  Google Scholar 

  7. Eastwood JB, Curtis JR, Smith EKM, et al. Shedding of nails apparently induced by the administration of large amounts of cephaloridine and cloxacillin in two anephric patients. Br J Dermatol 1969; 81: 750–2

    Article  PubMed  CAS  Google Scholar 

  8. Baran R, Témime P. Les onychodystrophies toxi-medicament-euses et les onycholyses. Concours Med 1973; 95: 1007–23

    Google Scholar 

  9. Chapman S, Cohen PR. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J 1997; 90: 395–8

    Article  PubMed  CAS  Google Scholar 

  10. Thomas HM. Transverse bands in fingernails. Bull Johns Hopkins Hosp 1964; 115: 238–44

    PubMed  Google Scholar 

  11. Miller E. Levodopa and nail growth. N Engl J Med 1973; 208: 916

    Google Scholar 

  12. de Doncker P, Pierard GE. Acquired nail beading in patients receiving itraconazole — an indicator of faster nail growth?: a study using optical profilometry. Clin Exp Dermatol 1994; 19: 404–6

    Article  PubMed  CAS  Google Scholar 

  13. Shelley WB, Shelley ED. A dermatologic diary: portrait of a practice. Cutis 1992; 49: 385–92

    PubMed  CAS  Google Scholar 

  14. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984; 4: 677–8

    Article  Google Scholar 

  15. Knight JF. Side benefits of the pill [letter]. Med J Aust 1974; Nov: 680

  16. Chang JC. Acute bullous dermatosis and onycholysis due to high-dose methotrexate and leucovorin calcium. Arch Dermatol 1987; 123: 990–2

    Article  PubMed  CAS  Google Scholar 

  17. Baran R. Action thérapeutique et complications du rétinoide aromatique sur l’appareil unguéal. Ann Dermatol Venereol 1982; 109: 367–71

    PubMed  CAS  Google Scholar 

  18. Baran R. Les onycholyses. Ann Dermatol Venereol 1986; 113: 159–70

    PubMed  CAS  Google Scholar 

  19. Baran R, Juhlin L. Drug induced photo-onycholysis: three sub types identified in a study of 15 cases. J Am Acad Dermatol 1987; 17: 1012–6

    Article  PubMed  CAS  Google Scholar 

  20. Jeanmougin M, Morel P, Civatte J. Photoonycholyse induite par la doxycycline. Ann Dermatol Venereol 1982; 109: 165–6

    PubMed  CAS  Google Scholar 

  21. Mackie RM. Onycholysis occurring during PUVAtherapy. Clin Exp Dermatol 1979; 4: 111–3

    Article  PubMed  CAS  Google Scholar 

  22. Zala L, Omar A, Krebs A. Photo-onycholysis induced by 8-methoxypsoralen. Dermatologica 1977; 154: 203–15

    Article  PubMed  CAS  Google Scholar 

  23. Baran R, Brun P. Photo-onycholysis induced by the fluoro-quinolones pefloxacine and ofloxacine. Dermatologica 1986; 176: 185–8

    Article  Google Scholar 

  24. Shelley WB, Humprey GB. Transverse leukonychia (Mees’ lines) due to daunorubicin chemotherapy. Pediatr Dermatol 1997; 14: 144–5

    Article  PubMed  CAS  Google Scholar 

  25. Muehrcke RC. The fingernails in chronic hypoalbuminaemia [letter]. BMJ 1956; 1: 1327

    Article  PubMed  CAS  Google Scholar 

  26. James WD, Odom RB. Chemotherapy-induced transverse white lines in the fingernails. Arch Dermatol 1983; 119: 334–5

    Article  PubMed  CAS  Google Scholar 

  27. Wantzin GL, Thomsen K. Acute paronychia after high-dose methotrexate therapy. Arch Dermatol 1983; 119: 623–4

    Article  PubMed  CAS  Google Scholar 

  28. Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 1986; 11: 148–52

    Article  PubMed  CAS  Google Scholar 

  29. Zerboni R, Angius AG, Cusini M, et al. Lamivudine-induced paronychia [letter]. Lancet 1998; 351: 1256

    Article  PubMed  CAS  Google Scholar 

  30. Bouscarat F, Bouchard C, Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 1998; 338: 1776–7

    Article  PubMed  CAS  Google Scholar 

  31. Tosti A, Piraccini BM, D’Antuono A, et al. Paronychia associated with antiretroviral therapy. Br J Dermatol 1999; 140: 1165–8

    Article  PubMed  CAS  Google Scholar 

  32. Baran R, Perrin C. Fixed drug eruption presenting as an acute paronychia. Br J Dermatol 1991; 125: 592–5

    Article  PubMed  CAS  Google Scholar 

  33. Huinink WWB, Prove AM, Piccart M, et al. A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527–32

    Google Scholar 

  34. Positano RG, De Lauro TM, Berkowitz BJ. Nail changes secondary to environmental influences. Clin Podiatr Med Surg 1989; 6: 417–29

    PubMed  CAS  Google Scholar 

  35. Varotti C, Ghetti E, Piraccini BM, et al. Subungual hematomas in a patient treated with an oral anticoagulant (warfarin sodium). Eur J Dermatol 1997; 7: 395–6

    Google Scholar 

  36. Vogelzang JN, Bosl GJ, Johnson K, et al. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Annlnt Med 1981; 95: 288–92

    CAS  Google Scholar 

  37. Snauwaert J, Degreef H. Bleomycin-induced Raynaud’s phenomenon and acral sclerosis. Dermatologica 1984; 169: 172–4

    Article  PubMed  CAS  Google Scholar 

  38. Dompmartin A, Le Maitre M, Letessier D, et al. Necroses digitales sous beta-bloquants. Ann Dermatol Venereol 1988; 115: 593–6

    PubMed  CAS  Google Scholar 

  39. Tosti A, Piraccini BM, Baran R. The melanocyte system of the nails and its disorders. In: Nordlund JJ, Boissy RE, Hearing VJ, et al, editors. The pigmentary system. New York: Oxford University Press, 1998; 937–43

    Google Scholar 

  40. Nixon DW. Alterations in nail pigment with cancer chemotherapy. Arch Int Med 1976; 136: 1117–8

    Article  CAS  Google Scholar 

  41. Tosti A, Gaddoni G, Fanti PA, et al. Longitudinal melanonychia induced by 3’-azidodeoxythymidine. Dermatologica 1990; 180: 217–20

    Article  PubMed  CAS  Google Scholar 

  42. Shelley WB, Rawnsley HM, Pillsbury DM. Postirradiation melanonychia. Arch Dermatol 1964; 90: 174–6

    Article  PubMed  CAS  Google Scholar 

  43. Urabe K, Nakayama J, Hori Y. Mixed epidermal and dermal hypermalanosis. In: Nordlund JJ, Boissy RE, Hearing VJ, et al, editors. The pigmentary system. New York: Oxford University Press, 1998; 909–35

    Google Scholar 

  44. Hendricks AA. Yellow lunulae with fluorescence after tetracycline therapy. Arch Dermatol 1980; 116: 438–40

    Article  PubMed  CAS  Google Scholar 

  45. Tosti A, Piraccini BM, Guerra L, et al. Reversible melanonychia due to clofazimine [abstract no.183 A]. 18th World Congress of Dermatology; 1992 Jun 12–18; New York, 183

    Google Scholar 

  46. Fam AG, Paton TW. Nail pigmentation after parenteral gold therapy for rheumatoid arthritis: ‘gold nails’. Arthritis Rheum 1984; 27: 119–20

    Article  PubMed  CAS  Google Scholar 

  47. Pepine M, Flowers FP, Ramos-Caro F. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol 1993; 28: 292–5

    Article  PubMed  CAS  Google Scholar 

  48. Tuffanelli D, Abraham RK, Dubois EL. Pigmentation from anti-malarial therapy. Arch Dermatol 1963; 88: 113–20

    Article  Google Scholar 

  49. Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997–1004

    Article  PubMed  CAS  Google Scholar 

  50. Baran R, Kechijian P. Longitudinal melanonychia: diagnosis and management. J Am Acad Dermatol 1989; 21: 1165–75

    Article  PubMed  CAS  Google Scholar 

  51. Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. Cutis 1993; 51: 303–5

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Bologna, Via Massarenti, 1, 40138, Bologna, Italy

    Bianca Maria Piraccini &  Antonella Tosti

Authors
  1. Bianca Maria Piraccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonella Tosti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonella Tosti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piraccini, B.M., Tosti, A. Drug-Induced Nail Disorders. Drug-Safety 21, 187–201 (1999). https://doi.org/10.2165/00002018-199921030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199921030-00004

Keywords

Search

Navigation